Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
J Rheumatol. 2019 Jan;46(1):7-18. DOI: 10.3899/jrheum.171361
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
J Rheumatol. 2019 Jan;46(1):7-18. DOI: 10.3899/jrheum.171361
Clinical Rheumatology 2018;37:2381–90 DOI 10.1007/s10067-018-4221-0
Arthritis Rheumatol 2018;70:1200–08 DOI 10.1002/art.40493
ADV Ther 2018; 35(10):1525–63 DOI: 10.1007/s12325-018-0757-2
Ann Rheum Dis 2018; 77:1268–1275 DOI: 10.1093/rheumatology/key121
Rheumatology 2018;57:1423–1431 DOI: 10.1093/rheumatology/key121
Pharmacoeconomics. 2018 Dec;36(12):1427-1437. doi: 10.1007/s40273-018-0677-7
Lancet 2018;391:2513–24
RMD Open. 2018 May 8;4(1):e000662. DOI: 10.1136/rmdopen-2018-000662